NCT04873583Toboroz3. fázis
High Dose Steroids in Children With Stroke
High Dose Steroids in Children With Stroke and Unilateral Focal Arteriopathy: A Multicentre Randomized Controlled Trial PASTA (Paediatric Arteriopathy Steroid Aspirin) Trial
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2025. nov. 18.
Rövid összefoglaló (regiszter, angolul)
This clinical trial deals with focal cerebral arteriopathy and childhood stroke, a rare but devastating condition. Focal cerebral arteriopathy (FCA) is an inflammatory vessel wall disease provoked by infection and there is increasing evidence that inflammatory processes play a crucial role in childhood stroke, influencing the outcome of the disease. Analysis of existing data suggests that outcomes are improved and that there is less stroke recurrence in children treated with steroids to reduce the acute inflammatory processes. This clinical trial will be conducted in over 20 hospitals in several countries in order to investigate this. Participants will be randomly separated into two groups. The first group will be treated with standard of care (including aspirin) combined with high dose steroids. The second group will be treated with standard of care (including aspirin) but without steroid treatment. The objective is to investigate if children treated with a combination of high dose steroid and aspirin will have a better and quicker recovery of FCA, better clinical functional outcome, and less recurrence compared to children treated with aspirin alone. This project has been identified by international pediatric stroke experts as the most important topic for a clinical trial in the field and is as well one of the most important research priorities identified by parents. The study results will also provide insight into the evolution of inflammatory vessel disease.
- Állapot (regiszter)
- Toboroz
- Fázis (regiszter)
- 3. fázis
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 70 (tervezett)
- Első benyújtás
- 2021. ápr. 15.
- Kezdés
- 2021. nov. 16.
- Elsődleges befejezés
- 2026. júl.
- Fő szponzor
- Insel Gruppe AG, University Hospital Bern
- Betegségek
- Stroke (szélütés)
- NCT-szám
- NCT04873583
- EU CT-szám
- 2022-500631-36-00
- EudraCT-szám
- 2021-005571-39
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó · 3. fázis
- Tervezett résztvevők: 70
- 2021. nov. 16. és az elsődleges befejezés (2026. júl.) között
- 40 helyszín, 11 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Korábbi kezelés
- Previous stroke
- Contraindication to steroid treatment as e.g. a congenital or acquired immunodeficiency
Más betegség
- Known syndromal disorders, as e.g. Trisomy 21, Neurofibromatosis type 1
- Known genetic vasculopathies as e.g. posterior fossa anomalies, hemangioma, arterial anomalies, cardiac anomalies and eye anomalies syndrome (PHACES), actin alpha 2 (ACTA II)
- Moyamoya or sickle cell disease
- Evidence of underlying systemic disorders, as e.g. lupus, rheumatoid problems
- Secondary CNS angiitis due to infections (meningitis, endocarditis, borreliosis), or generalised angiitis due to rheumatic or other autoimmune problems
- On steroid treatment at disease onset
- Participation in another interventional study within the 30 days preceding the indication stroke and during the present study
Egyéb
- Small vessel cerebral vasculitis (primary CNS vasculitis)
- Bilateral arteriopathy
- Arterial dissection(s)
- Progressive large to medium childhood primary angiitis of the CNS (cPACNS ) with 2 of the following 3 criteria:
- pre-existing progressive neurocognitive dysfunction
- bilateral MRI lesions/vessel involvement
- small vessel arterial stenosis
- Inability to follow the procedures of the study, e.g. due to language problems
Kiket keres a vizsgálat
- Informed consent of the legal representative of the trial participant documented by signature
- Age > 6 months \& < 18 years at time of stroke
- Randomisation possible within 48 hours of diagnosis and maximum 96 hours after stroke onset
- Unilateral arteriopathy according to the following criteria:
- Newly acquired neurologic deficits
- Specific neuroimaging (MRA) features of either
- unilateral stenosis, or
- unilateral vessel irregularities within the Central Nervous System (CNS)
- Unless otherwise defined in the national addendum: Female participants age ≥ 13: Negative pregnancy test (blood or urine)
Életkor a regiszterben: 6 hónap – 17 év · Nem: nők és férfiak · Egészséges önkénteseket nem fogad
Helyszínek (40)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.